PMID- 37124216
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20230502
IS  - 1663-9812 (Print)
IS  - 1663-9812 (Electronic)
IS  - 1663-9812 (Linking)
VI  - 14
DP  - 2023
TI  - Safety and efficacy of Xiaoyao-san for the treatment of functional dyspepsia: a 
      systematic review and meta-analysis of randomized controlled trials.
PG  - 1114222
LID - 10.3389/fphar.2023.1114222 [doi]
LID - 1114222
AB  - Objective: Although Xiaoyao-san (XYS) is a popular herbal remedy for indigestion, 
      there is insufficient evidence to recommend it as a treatment option for 
      functional dyspepsia (FD). This review aimed to assess the safety and efficacy of 
      XYS in patients with FD, compared to conventional Western medicine (WM). Methods: 
      Two independent reviewers searched for randomized controlled trials (RCTs) using 
      11 electronic databases, including Medline and Embase, to evaluate therapeutic 
      effects of XYS on FD up to 31 January 2023. The primary outcome was the total 
      clinical efficacy rate (TCE), and secondary outcomes included scores of 
      dyspepsia-related symptoms (DSS) and incidence of adverse events (AEs). The risk 
      of bias was evaluated using the Cochrane collaboration tool, and data synthesis 
      and subgroup analyses were performed using the Review Manager program. Results: 
      Six studies involving 707 participants were included in the meta-analysis. XYS 
      significantly improved TCE compared to WM (RR = 1.15, 95% CI: 1.05, 1.26, p = 
      0.002) with high heterogeneity (I (2) = 59%, p = 0.06). Combination therapy also 
      showed higher TCE than WM alone (RR = 1.22, 95% CI: 1.05, 1.41, p = 0.008), and 
      the heterogeneity was low (I (2) = 0%, p = 0.86). The results showed a greater 
      reduction in DSS in the XYS and combination therapy groups than in the WM alone 
      group (SMD = -0.72, 95% CI: -0.90, -0.53, p < 0.00001) with low heterogeneity (I 
      (2) = 44%, p = 0.15), especially for abdominal distension and upper abdominal 
      pain. AEs occurred less frequently in the XYS and combination therapy groups than 
      in the WM alone group (RR = 0.20, 95% CI: 0.07, 0.63, p = 0.006), and the 
      heterogeneity was low (I (2) = 45%, p = 0.18). The certainty of the evidence for 
      each outcome was rated from "very low" to "high." Conclusion: This review 
      suggests that XYS is effective and safe for reducing complaints in patients with 
      FD. However, high-quality RCTs should be conducted to establish more convincing 
      therapeutic evidence of XYS for the treatment of FD. Systematic Review 
      Registration: https://www.crd.york.ac.uk/prospero, CRD42020178842.
CI  - Copyright (c) 2023 Ha, Lee, Jeong, Ko, Park and Kim.
FAU - Ha, Na-Yeon
AU  - Ha NY
AD  - Division of Digestive Diseases, Department of Internal Korean Medicine, Kyung Hee 
      University Medical Center, Seoul, Republic of Korea.
FAU - Lee, Hanul
AU  - Lee H
AD  - Division of Digestive Diseases, Department of Internal Korean Medicine, Kyung Hee 
      University Medical Center, Seoul, Republic of Korea.
FAU - Jeong, Haein
AU  - Jeong H
AD  - Department of Clinical Korean Medicine, Graduate School, Kyung Hee University, 
      Seoul, Republic of Korea.
FAU - Ko, Seok-Jae
AU  - Ko SJ
AD  - Department of Gastroenterology, Kyung Hee University College of Korean Medicine, 
      Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
FAU - Park, Jae-Woo
AU  - Park JW
AD  - Department of Gastroenterology, Kyung Hee University College of Korean Medicine, 
      Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.
FAU - Kim, Jinsung
AU  - Kim J
AD  - Department of Gastroenterology, Kyung Hee University College of Korean Medicine, 
      Kyung Hee University Medical Center, Seoul, Republic of Korea.
LA  - eng
PT  - Systematic Review
DEP - 20230412
PL  - Switzerland
TA  - Front Pharmacol
JT  - Frontiers in pharmacology
JID - 101548923
PMC - PMC10130649
OTO - NOTNLM
OT  - Soyo-san
OT  - Xiaoyao-san
OT  - functional dyspepsia
OT  - herbal medicine
OT  - meta-analysis
OT  - systematic review
COIS- The authors declare that the research was conducted in the absence of any 
      commercial or financial relationships that could be construed as a potential 
      conflict of interest.
EDAT- 2023/05/01 06:42
MHDA- 2023/05/01 06:43
PMCR- 2023/04/12
CRDT- 2023/05/01 03:40
PHST- 2022/12/02 00:00 [received]
PHST- 2023/04/03 00:00 [accepted]
PHST- 2023/05/01 06:43 [medline]
PHST- 2023/05/01 06:42 [pubmed]
PHST- 2023/05/01 03:40 [entrez]
PHST- 2023/04/12 00:00 [pmc-release]
AID - 1114222 [pii]
AID - 10.3389/fphar.2023.1114222 [doi]
PST - epublish
SO  - Front Pharmacol. 2023 Apr 12;14:1114222. doi: 10.3389/fphar.2023.1114222. 
      eCollection 2023.